471 related articles for article (PubMed ID: 16969649)
1. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.
Tan KC; Shiu SW; Chow WS; Leng L; Bucala R; Betteridge DJ
Diabetologia; 2006 Nov; 49(11):2756-62. PubMed ID: 16969649
[TBL] [Abstract][Full Text] [Related]
2. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes.
Tam XH; Shiu SW; Leng L; Bucala R; Betteridge DJ; Tan KC
Clin Sci (Lond); 2011 Jan; 120(2):81-9. PubMed ID: 20726839
[TBL] [Abstract][Full Text] [Related]
3. Plasma sRAGE is not associated with urinary microalbumin excretion in type 2 diabetic nephropathy at the early stage.
Yu JY; An XF; Liu JS; Ten SC; Wang X; Zhao Y; Huang S; Gu WJ; Gao F
Diabetes Res Clin Pract; 2010 Feb; 87(2):157-60. PubMed ID: 19945761
[TBL] [Abstract][Full Text] [Related]
4. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.
Basta G; Sironi AM; Lazzerini G; Del Turco S; Buzzigoli E; Casolaro A; Natali A; Ferrannini E; Gastaldelli A
J Clin Endocrinol Metab; 2006 Nov; 91(11):4628-34. PubMed ID: 16926247
[TBL] [Abstract][Full Text] [Related]
5. Association of the receptor for advanced glycation end products (RAGE) -374 T/A gene polymorphism and circulating soluble RAGE with nephropathy in type 1 diabetic patients.
Abdel-Azeez HA; El-Okely AM
Egypt J Immunol; 2009; 16(1):95-106. PubMed ID: 20726326
[TBL] [Abstract][Full Text] [Related]
6. Advanced glycation end products (AGEs) and their soluble receptors (sRAGE) as early predictors of reno-vascular complications in patients with uncontrolled type 2 diabetes mellitus.
Farhan SS; Hussain SA
Diabetes Metab Syndr; 2019; 13(4):2457-2461. PubMed ID: 31405660
[TBL] [Abstract][Full Text] [Related]
7. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease.
Nakamura K; Yamagishi S; Adachi H; Kurita-Nakamura Y; Matsui T; Yoshida T; Sato A; Imaizumi T
Diabetes Metab Res Rev; 2007 Jul; 23(5):368-71. PubMed ID: 17024691
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
[TBL] [Abstract][Full Text] [Related]
9. Serum advanced glycation end-products and receptors as prognostic biomarkers in diabetics undergoing coronary artery stent implantation.
Shen Y; Pu LJ; Lu L; Zhang Q; Zhang RY; Shen WF
Can J Cardiol; 2012; 28(6):737-43. PubMed ID: 23073352
[TBL] [Abstract][Full Text] [Related]
10. Soluble RAGE, diabetic nephropathy and genetic variability in the AGER gene.
Kanková K; Kalousová M; Hertlová M; Krusová D; Olsovský J; Zima T
Arch Physiol Biochem; 2008 Apr; 114(2):111-9. PubMed ID: 18615900
[TBL] [Abstract][Full Text] [Related]
11. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function.
Gohda T; Tanimoto M; Moon JY; Gotoh H; Aoki T; Matsumoto M; Shibata T; Ohsawa I; Funabiki K; Tomino Y
Diabetes Res Clin Pract; 2008 Aug; 81(2):196-201. PubMed ID: 18550199
[TBL] [Abstract][Full Text] [Related]
12. Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function.
Kajikawa M; Nakashima A; Fujimura N; Maruhashi T; Iwamoto Y; Iwamoto A; Matsumoto T; Oda N; Hidaka T; Kihara Y; Chayama K; Goto C; Aibara Y; Noma K; Takeuchi M; Matsui T; Yamagishi S; Higashi Y
Diabetes Care; 2015 Jan; 38(1):119-25. PubMed ID: 25336748
[TBL] [Abstract][Full Text] [Related]
13. Association between acute-phase reactants and advanced glycation end products in type 2 diabetes.
Tan KC; Chow WS; Tam S; Bucala R; Betteridge J
Diabetes Care; 2004 Jan; 27(1):223-8. PubMed ID: 14693993
[TBL] [Abstract][Full Text] [Related]
14. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients.
Kerkeni M; Saïdi A; Bouzidi H; Letaief A; Ben Yahia S; Hammami M
Diab Vasc Dis Res; 2013 May; 10(3):239-45. PubMed ID: 23091285
[TBL] [Abstract][Full Text] [Related]
15. Independent determinants of soluble form of receptor for advanced glycation end products in elderly hypertensive patients.
Nakamura K; Adachi H; Matsui T; Kurita Y; Takeuchi M; Yamagishi S
Metabolism; 2009 Mar; 58(3):421-5. PubMed ID: 19217461
[TBL] [Abstract][Full Text] [Related]
16. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Yamagishi S; Matsui T; Nakamura K
Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
[TBL] [Abstract][Full Text] [Related]
17. Association of four differently processed diets with plasma and urine advanced glycation end products and serum soluble receptor for advanced glycation end products concentration in healthy dogs.
Bridglalsingh S; Archer-Hartmann S; Azadi P; Barbier de La Serre C; Remillard RL; Sunvold GD; Bartges JW
J Anim Physiol Anim Nutr (Berl); 2024 May; 108(3):735-751. PubMed ID: 38279966
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients.
Oz Gul O; Tuncel E; Yilmaz Y; Ulukaya E; Gul CB; Kiyici S; Oral AY; Guclu M; Ersoy C; Imamoglu S
Metabolism; 2010 Jan; 59(1):64-9. PubMed ID: 19709689
[TBL] [Abstract][Full Text] [Related]
19. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.
Yamagishi S; Adachi H; Nakamura K; Matsui T; Jinnouchi Y; Takenaka K; Takeuchi M; Enomoto M; Furuki K; Hino A; Shigeto Y; Imaizumi T
Metabolism; 2006 Sep; 55(9):1227-31. PubMed ID: 16919543
[TBL] [Abstract][Full Text] [Related]
20. Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes.
Yu Y; Hanssen KF; Kalyanaraman V; Chirindel A; Jenkins AJ; Nankervis AJ; Torjesen PA; Scholz H; Henriksen T; Lorentzen B; Garg SK; Menard MK; Hammad SM; Scardo JA; Stanley JR; Wu M; Basu A; Aston CE; Lyons TJ
BJOG; 2012 Nov; 119(12):1512-20. PubMed ID: 22900949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
